Updates are available Correction dated 2025-05-30
Click to view Correction: https://doi.org/10.1038/s41598-025-01649-0
-
Authors
Gulzar, Ayesha
Kaleli, Humeyra N
Köseoğlu, Gülsüm D
Hasanreisoğlu, Murat
Yıldız, Ayşe
Şahin, Afsun
Kizilel, Seda
-
Funding
Funding for this research was provided by:
Türkiye Bilimsel ve Teknolojik Araştırma Kurumu (219S349)
- License Information
-
More Information
Article History
Received: 20 May 2024
Accepted: 2 September 2024
First Online: 23 October 2024
Change Date: 30 May 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-025-01649-0
Competing interests
: The authors S.K., A.Ş., A.Y., and A.G. are inventors and have filled a patent through the Koc University (A METHOD AND A PHARMACEUTICAL COMPOSITION FOR VISIBLE LIGHT-INDUCED CORNEAL CROSSLINKING WITH RUTHENIUM COMPOUNDS FOR THE TREATMENT OF EYE DISORDERS, application number PCT/TR2022/050954, in process) for the use of ruthenium for corneal collagen crosslinking. All the remaining authors declare no conflict of interest.
